Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

Author(s): M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell and R. J. Mairs

Volume 1, Issue 1, 2004

Page: [50 - 57] Pages: 8

DOI: 10.2174/1570180043485743

Abstract

Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.

Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft


© 2024 Bentham Science Publishers | Privacy Policy